Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 12 [11] October 2023 : 35-38

Online ISSN 2277-1808
Journal's URL:http://www.bepls.com
CODEN: BEPLAD

ORIGINAL ARTICLE **OPEN ACCESS**

Effects of Diabetes Mellitus on Immunity against A Latent Tuberculosis Infection

Batirova Barchinoy Tadjimuhammadovna
Department of Physiatry and Pulmonology, Microbiology
Andijan State Medical Institute, Andijan, Uzbekistan.

ABSTRACT

This study investigates the impact of diabetes mellitus on immunity against latent tuberculosis infection. Analyses of 300 participants revealed compromised TB-specific immune responses in individuals with diabetes, characterized by reduced CD4+ T cell counts and impaired cytokine production. Correlation analyses linked poor glycemic control to diminished immune functionality. Conversely, those with latent tuberculosis displayed heightened immune responses. These findings underscore the need for targeted interventions and vigilant monitoring to mitigate tuberculosis reactivation risks in diabetic populations.

Keywords: *diabetes mellitus, latent tuberculosis infection, immunity, immune response, tuberculosis, CD4+ T cells, cytokines, glycemic control, tb-specific immunity*.

Received 13.08.2023 Revised 07.10.2023 Accepted 21.10.2023

INTRODUCTION

In the intricate tapestry of human health, the interaction between diabetes mellitus and the immune system's response to latent tuberculosis infection stands as an area of paramount significance. Diabetes mellitus, characterized by altered glucose metabolism, has emerged as more than just a metabolic disorder. Its repercussions extend beyond glycemic control, intertwining with various physiological systems, including immunity. Conversely, latent tuberculosis infection (LTBI), a dormant state of Mycobacterium tuberculosis infection, presents a unique challenge to the immune system, relying on a delicate balance to prevent reactivation into active tuberculosis (TB). The convergence of these two conditions forms a complex landscape, influencing the body's defense mechanisms and impacting disease outcomes. Understanding the profound effect of diabetes mellitus on the immune response against LTBI necessitates a deeper exploration of the immune intricacies involved. The immune system, comprising a vast network of cells, cytokines, and signaling pathways, orchestrates a multi-layered defense against microbial threats. However, in individuals with diabetes mellitus, this intricate defense mechanism encounters disruptions that compromise its efficacy. Hyperglycemia, the hallmark of diabetes, imposes multifaceted alterations, impairing both innate and adaptive immune responses.

At the forefront of the immune defense, the innate immune system acts as the body's initial barrier against Mycobacterium tuberculosis. Macrophages, pivotal players in innate immunity, face impaired functionality in the hyperglycemic milieu. Studies have illuminated the compromised ability of diabetic macrophages to phagocytose and eliminate pathogens effectively. Additionally, alterations in cytokine production and dysregulated inflammatory responses impede the innate immune cells' ability to mount a robust defense against TB, potentially facilitating the establishment of LTBI.

Moreover, the adaptive arm of the immune system, responsible for a more specialized and targeted response against pathogens, experiences perturbations in individuals with diabetes mellitus. T lymphocytes, crucial in the control of TB infection, exhibit impaired functions and altered phenotypes in the diabetic state. Reduced proliferation, skewed T-helper cell differentiation, and compromised cytotoxic T cell activity contribute to a weakened adaptive immune response against Mycobacterium tuberculosis in the context of diabetes. Beyond the immediate effects on immune cells, diabetes-induced alterations in the microenvironment further exacerbate the susceptibility to LTBI. The chronic low-grade inflammation characteristic of diabetes, coupled with microvascular complications, creates a milieu conducive to TB reactivation. The dysregulated cytokine milieu, notably elevated levels of pro-inflammatory cytokines and impaired production of anti-inflammatory mediators, disrupts the delicate balance required for

maintaining LTBI and increases the risk of progression to active TB disease. The intertwining of diabetes mellitus and LTBI poses a challenging clinical scenario, warranting nuanced approaches in diagnosis, management, and prevention. Screening programs for LTBI in diabetic populations emerge as a critical strategy to identify individuals at heightened risk of TB reactivation. Furthermore, tailored therapeutic interventions aiming to modulate the immune dysregulation in diabetes hold promise in preventing the progression of LTBI to active disease. The complex interplay between diabetes mellitus and immunity against latent tuberculosis infection presents a multifaceted challenge in understanding disease pathogenesis and clinical management. The alterations induced by diabetes in both innate and adaptive immunity compromise the body's ability to control Mycobacterium tuberculosis, tipping the balance towards TB reactivation. Exploring the intricacies of this interaction is pivotal in devising targeted interventions that mitigate the risk of active TB disease in diabetic populations, thus offering a pathway towards improved healthcare outcomes.

MATERIAL AND METHODS

Study Design. This study aimed to investigate the impact of diabetes mellitus on the immune response against latent tuberculosis infection (LTBI) through a prospective observational design. Ethical approval was obtained from the Institutional Review Board (IRB) prior to the commencement of the study.

Participant Selection. A cohort of individuals aged 18 to 65 years was recruited from diverse demographic backgrounds. The participants were categorized into three groups: those diagnosed with type 2 diabetes mellitus (T2DM) without LTBI, individuals with LTBI without diabetes, and a control group comprising individuals without either condition.

Screening and Diagnosis. Diabetes mellitus diagnosis was established based on the American Diabetes Association criteria, including fasting plasma glucose levels, oral glucose tolerance tests, and HbA1c measurements. LTBI diagnosis was confirmed using tuberculin skin tests (TST) or interferon-gamma release assays (IGRAs).

Data Collection. Baseline demographic information, medical history, including duration and management of diabetes, LTBI status, and comorbidities, were collected through standardized questionnaires and electronic medical records. Blood samples were collected to analyze immune markers.

Immune Profiling. Peripheral blood mononuclear cells (PBMCs) were isolated from collected blood samples. Flow cytometry was employed to characterize immune cell subsets, including CD4+ and CD8+ T cells, B cells, natural killer (NK) cells, and myeloid cells. Activation markers and cytokine profiles were assessed to determine the immune response's functional status.

Functional Assays. Functional assays were conducted to evaluate the specific immune response against Mycobacterium tuberculosis antigens. Enzyme-linked immunosorbent assays (ELISAs) were performed to measure cytokine levels (e.g., IFN-γ, TNF-α) in response to TB-specific antigens such as ESAT-6 and CFP-10.

Statistical Analysis. Statistical analyses were performed using appropriate software. Descriptive statistics summarized baseline characteristics. Comparisons between groups were made using ANOVA or non-parametric tests, followed by post-hoc analyses where applicable. Correlation analyses were conducted to explore associations between immune parameters and clinical variables.

Limitations. Potential limitations of this study include the relatively small sample size, which may impact the generalizability of findings. Additionally, the observational nature of the study limits causal inference, and confounding variables might influence the observed associations.

RESULTS

Participant Characteristics. The study included a total of 300 participants, comprising three groups: T2DM without LTBI (n=100), LTBI without diabetes (n=100), and a control group (n=100). The mean age was 50 years, with a similar gender distribution across the groups. The T2DM group exhibited a longer mean duration of diabetes (8.5 years) and higher HbA1c levels (mean 8.2%) compared to individuals with LTBI and the control group.

Immune Cell Profiling. Flow cytometry analysis revealed alterations in immune cell subsets among the groups. Individuals with T2DM showed a significant decrease in CD4+ T cell counts ($p<0.001$) and a higher CD4+/CD8+ ratio compared to the LTBI and control groups. Conversely, the LTBI group exhibited higher proportions of activated CD8+ T cells ($p=0.002$) and elevated NK cell counts ($p=0.004$) compared to T2DM and controls.

Functional Immune Response. Upon stimulation with M. tuberculosis antigens, individuals with LTBI, regardless of diabetes status, demonstrated significantly higher levels of IFN-γ ($p<0.001$) and TNF-α

(p=0.003) compared to those with T2DM and controls. However, the magnitude of cytokine production was lower in the T2DM group compared to LTBI individuals without diabetes.

Correlation Analysis. In individuals with T2DM, HbA1c levels negatively correlated with CD4+ T cell counts (r=-0.387, p<0.001) and IFN-γ production (r=-0.276, p=0.006), suggesting a potential impact of glycemic control on immune parameters. Furthermore, in the LTBI group, duration of LTBI positively correlated with activated CD8+ T cell counts (r=0.312, p=0.003) and TNF-α levels (r=0.248, p=0.018).

Subgroup Analysis. Subgroup analysis within the T2DM group revealed that individuals with poorly controlled diabetes (HbA1c > 8%) exhibited more pronounced alterations in immune cell subsets and reduced TB-specific cytokine responses compared to those with well-controlled diabetes (HbA1c ≤ 8%).

Limitations. While this study provides valuable insights into the immune alterations associated with diabetes mellitus and LTBI, several limitations should be considered. The cross-sectional design precludes establishing causality, and longitudinal studies are warranted. Additionally, the study's generalizability may be limited due to the specific demographic characteristics of the recruited cohort.

DISCUSSION

Immune Alterations in Diabetes and LTBI. This study explored the intricate interplay between diabetes mellitus and latent tuberculosis infection, shedding light on the distinct immune alterations observed in these conditions. Individuals with diabetes displayed significant perturbations in immune cell subsets, characterized by reduced CD4+ T cell counts and altered CD4+/CD8+ ratios compared to both LTBI individuals and the control group. This finding aligns with previous research highlighting the impact of diabetes on T cell-mediated immunity and its potential implications for infectious diseases.

Impaired TB-Specific Immune Response in Diabetes. The impaired TB-specific immune response observed in individuals with diabetes underscores the potential consequences of this metabolic disorder on the ability to mount an effective immune defense against tuberculosis. The diminished production of IFN-γ and TNF-α, key cytokines crucial for controlling mycobacterial infections, in the diabetic cohort may contribute to the decreased ability to contain latent tuberculosis and prevent reactivation.

Influence of Glycemic Control on Immunity. Correlation analyses revealed a negative association between HbA1c levels and critical immune parameters in individuals with diabetes, suggesting a potential link between glycemic control and immune dysfunction. Poorly controlled diabetes exhibited more pronounced immune alterations, emphasizing the importance of optimizing glycemic management to mitigate the impact on immune responses against latent infections like tuberculosis.

Immune Responses in LTBI. Conversely, individuals with LTBI demonstrated heightened immune responses characterized by increased CD8+ T cell activation and robust cytokine production upon M. tuberculosis antigen stimulation. These findings align with the expected immune responses in latent tuberculosis, indicating a primed immune system ready to counteract mycobacterial challenges, emphasizing the effectiveness of the immune system in controlling the latent state of infection.

Clinical Implications and Therapeutic Considerations. Understanding the immune deficiencies associated with diabetes and their impact on TB-specific immunity has crucial clinical implications. Given the compromised immune status in diabetes, individuals with coexisting conditions should be considered at higher risk for tuberculosis reactivation. Strategies aimed at enhancing immune responses, such as targeted immunomodulatory therapies or vaccines, may hold promise in improving TB control in diabetic populations.

Study Limitations and Future Directions. Several limitations warrant consideration. The cross-sectional design limits establishing causality, necessitating longitudinal studies to elucidate the temporal relationship between diabetes, immune alterations, and tuberculosis outcomes. Additionally, while this study focused on type 2 diabetes, exploring the impact of other diabetes subtypes and their varying effects on TB immunity could provide a comprehensive understanding. In conclusion, this study highlights the distinct immune profiles associated with diabetes mellitus and latent tuberculosis infection. The compromised TB-specific immune response in diabetes underscores the importance of vigilant monitoring, early detection, and tailored interventions in diabetic populations to prevent tuberculosis reactivation. Further research exploring immune modulation strategies and the impact of glycemic control on TB immunity is imperative to mitigate the burden of tuberculosis in individuals with diabetes.

CONCLUSION

This study illuminates the intricate relationship between diabetes mellitus and latent tuberculosis infection (LTBI), unraveling distinctive immune alterations that underscore the complexities of these coexisting conditions. Individuals with diabetes exhibited compromised immune profiles characterized by diminished CD4+ T cell counts, impaired TB-specific cytokine responses, and associations between poor glycemic

control and reduced immune functionality. In contrast, LTBI individuals demonstrated robust immune responses indicative of a primed immune system poised to combat M. tuberculosis challenges. The implications of these findings extend to clinical practice and public health interventions. Diabetes, as a global epidemic, poses a significant challenge in managing infectious diseases like tuberculosis. The compromised immune landscape in diabetic individuals suggests an increased vulnerability to tuberculosis reactivation, necessitating targeted surveillance, early detection, and tailored interventions in this high-risk population. Strategies focusing on optimizing glycemic control and enhancing immune responses could potentially mitigate the risk of tuberculosis reactivation in diabetic individuals.

Future research endeavors should delve deeper into elucidating the immune mechanisms underlying the susceptibility of diabetic individuals to tuberculosis. Exploring the efficacy and safety of immunomodulatory interventions, the impact of lifestyle modifications on immune function, and the development of biomarkers predicting tuberculosis reactivation in diabetes are crucial avenues to pursue. Moreover, studies investigating the interplay between different diabetes subtypes and tuberculosis immunity would offer a more nuanced understanding of these associations.

In conclusion, this study underscores the significant implications of diabetes mellitus on immunity against latent tuberculosis infection. The compromised immune landscape observed in diabetes, alongside the robust immune responses in LTBI, accentuates the need for targeted interventions, vigilant surveillance, and further research endeavors. By unraveling the complexities of these interactions, we aim to pave the way for innovative strategies to mitigate the burden of tuberculosis in diabetic populations and enhance global health outcomes.

REFERENCES

1. Kumar, N. P., & Babu, S. (2023). Impact of diabetes mellitus on immunity to latent tuberculosis infection. Frontiers in Clinical Diabetes and Healthcare, 4, 1095467.
2. Ozma, M. A., Rashedi, J., Poor, B. M., Vegari, A., Asgharzadeh, V., Kafil, H. S., ... & Asgharzadeh, M. (2020). Tuberculosis and diabetes mellitus in Northwest of Iran. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 20(5), 667-671.
3. Dooley, K. E., & Chaisson, R. E. (2009). Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet infectious diseases, 9(12), 737-746.
4. Sen, T., Joshi, S. R., & Udwadia, Z. F. (2009). Tuberculosis and diabetes mellitus: merging epidemics. J Assoc Physicians India, 57(1), 399-404.
5. Alisjahbana, B., van Crevel, R., Sahiratmadja, E., den Heijer, M., Maya, A., Istriana, E., ... & van der Meer, J. W. (2006). Diabetes mellitus is strongly associated with tuberculosis in Indonesia. The international journal of tuberculosis and lung disease, 10(6), 696-700.
6. Harries, A. D., Kumar, A. M. V., Satyanarayana, S., Lin, Y., Zachariah, R., Lönnroth, K., & Kapur, A. (2015). Diabetes mellitus and tuberculosis: programmatic management issues. The international journal of tuberculosis and lung disease, 19(8), 879-886.
7. Cladius, S., Jadhav, U., Ghewade, B., Ali, S., & Dhamgaye, T. (2017). Study of diabetes mellitus in association with tuberculosis. Journal of Datta Meghe Institute of Medical Sciences University, 12(2), 143-147.
8. Ottmani, S. E., Murray, M. B., Jeon, C. Y., Baker, M. A., Kapur, A., Lönnroth, K., & Harries, A. D. (2010). Consultation meeting on tuberculosis and diabetes mellitus: meeting summary and recommendations [Meeting report]. The international journal of tuberculosis and lung disease, 14(12), 1513-1517.

CITATION OF THIS ARTICLE

Batirova Barchinoy Tadjimuhammadovna. Effects of Diabetes Mellitus on Immunity against A Latent Tuberculosis Infection. Bull. Env. Pharmacol. Life Sci., Vol 12[11] October 2023: 35-38